Immunology and inflammation

News

MSD rumoured to be eyeing $3bn+ MoonLake takeover

Faced with the looming loss of patent protection for Keytruda, MSD is reported to be interested in buying Swiss immunology player MoonLake.

News

AbbVie closes on Rinvoq approval in inflamed artery disease

AbbVie's Rinvoq is poised to become the first oral targeted treatment for giant cell arteritis in the EU after being backed by the CHMP.

News

Insmed's chief medical officer Martina Flammer

FDA starts review of first bronchiectasis drug candidate

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for bronchiectasis in the US.

News

Lilly nets a second FDA okay for Omvoh, in Crohn's disease

Eli Lilly picks up a second FDA approval for IL-23 inhibitor Omvoh in Crohn's disease, but will it kickstart sales growth?

News

AbbVie adds psoriasis med with Nimble takeover

AbbVie agrees a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will add an oral peptide for psoriasis to its pipeline.

News

Novartis pays $150m upfront for Monte Rosa degrader drug

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion.

MSD rumoured to be eyeing $3bn+ MoonLake takeover

AbbVie closes on Rinvoq approval in inflamed artery disease

FDA starts review of first bronchiectasis drug candidate

Lilly nets a second FDA okay for Omvoh, in Crohn's disease

AbbVie adds psoriasis med with Nimble takeover

Novartis pays $150m upfront for Monte Rosa degrader drug

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks